Pan Cancer T is a Rotterdam-based biotech spin-out from Erasmus MC (founded in 2020) that engineers TCR-T cell therapies for hard-to-treat solid cancers. Its platform pairs broadly expressed tumour targets with proprietary technologies designed to enhance T-cell durability, aiming to improve efficacy against solid tumours. The lead program, PCT1:CO-STIM, is being prepared for a first-in-human trial in women with triple-negative breast cancer. Additional pipeline programs address malignancies of the skin, colorectum, stomach, oesophagus, ovary and uterus. To date the company has secured roughly €21 million in capital, comprising €2 million in grants, an Innovation Credit loan and multiple equity financings. The latest infusion strengthens its cash position to advance pre-clinical work through the clinic while expanding its broader solid-tumour pipeline. Existing investors continue to back the firm alongside non-dilutive government support, reflecting confidence in its differentiated approach.

Total raised

$16M

Funding rounds

3

Latest round

Grant

Latest activity

Dec 2025